Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

4
ESMO-MCBS v1.1
Scorecard version: 1

Indication details

Tumour Type
Thoracic Malignancies
Tumour Sub-type
Non-small-cell Lung Cancer
Tumour Sub-Group
EGFR+
Tumour stage
Locally advanced or metastatic
Control Arm
Cisplatin + pemetrexed
Treatment Setting
First-line EGFR TKI-naïve locally advanced or metastatic NSCLC with activating EGFR mutations
Trial Name
LUX - Lung 3

Primary Outcome(s)

Primary Outcome(s)
PFS (crossover allowed)
Form(s)
Form 2b

Outcome Data

PFS Control
6.9 months
PFS Gain
4.2 months
PFS HR
0.58 (0.43-0.78)
OS Control
28.2 months
OS Gain
0.0 months
OS HR
0.88 (0.66-1.17) not significant
QoL Comment
Improved

Final Score (after adjustments)

Preliminary non-curative score
3
QoL adjustment
1+
Final non-curative Score
4
Issue date
11.12.2018
Last update
05.05.2022

DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; HR, hazard ratio; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.